

## **North America Self-injections Market**

Market Report | 2024-09-01 | 302 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

### **Report description:**

North America self-injection market is expected to reach USD 41.75 billion by 2031 from USD 19.52 billion in 2023, growing with a CAGR of 10.2% in the forecast period of 2024 to 2031.

#### Market Segmentation:

North America Self-injections Market, By Product Type (Self-Injection Devices and Self-Injection Formulation), Dosage Form (Single Dose and Multi-Dose), Route of Administration (Subcutaneous, Intra muscular, and Others), Application (Autoimmune Diseases, Pain Management, Emergency Drugs, Oncology, Hormonal Disorders, and Others), Age Group (Adult, Geriatric, and Pediatric), Gender (Male and Female), Distribution Channel (Direct Tender, Hospital Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031

#### Overview of North America Self-Injections Market Dynamics:

##### Driver

- Rising prevalence of chronic disease

##### Restraint

- High cost of self injectors

##### Opportunity

- Government initiatives to self-injections

#### Market Players:

The key market players operating in the North America self-injection market are listed below:

- Novo Nordisk A/S
- Johnson & Johnson Services, Inc.
- Biogen
- Amgen Inc.
- Sanofi
- AbbVie Inc.
- YPSOMED
- BD
- AstraZeneca
- AptarGroup, Inc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Bayer AG
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- Credence Medsystems, Inc.
- Enable Injections
- F. Hoffmann-La Roche Ltd
- GSK plc
- Gerresheimer AG
- Haselmeier
- Ipsen Biopharmaceuticals, Inc.
- Lilly
- Midas Pharma GmbH
- Merck & Co., Inc.
- Novartis AG
- Namera
- OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)
- Owen Mumford
- Pfizer Inc.
- Philips-Medisize
- Pharmajet
- PenJet
- Recipharm AB
- SCHOTT PHARMA
- SHL Medical AG
- Societe Industrielle de Sonceboz SA
- Terumo Corporation
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- UCB Pharma
- West Pharmaceutical Service

## **Table of Contents:**

1 INTRODUCTION	52
1.1 OBJECTIVES OF THE STUDY	52
1.2 MARKET DEFINITION	52
1.3 OVERVIEW OF NORTH AMERICA SELF-INJECTIONS MARKET	52
1.4 MARKETS COVERED	55
2 MARKET SEGMENTATION	58
2.1 MARKETS COVERED	58
2.2 GEOGRAPHICAL SCOPE	59
2.3 YEARS CONSIDERED FOR THE STUDY	60
2.4 CURRENCY AND PRICING	60
2.5 DBMR TRIPOD DATA VALIDATION MODEL	61
2.6 MULTIVARIATE MODELLING	64

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

2.7 THERAPEUTICS LIFELINE CURVE	64
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	65
2.9 DBMR MARKET POSITION GRID	66
2.10 VENDOR SHARE ANALYSIS	67
2.11 MARKET APPLICATION COVERAGE GRID	68
2.12 SECONDARY SOURCES	69
2.13 ASSUMPTIONS	69
3 EXECUTIVE SUMMARY	70
4 PREMIUM INSIGHT	76
4.1 PORTER'S FIVE FORCES	77
4.2 PESTEL ANALYSIS	78
4.3 CUSTOMIZATIONS	79
5 NORTH AMERICA SELF-INJECTIONS MARKET: REGULATIONS	84
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION	84
5.1.1 AUSTRALIA	84
5.1.2 CHINA	86
5.1.3 INDIA	88
5.2 REGULATORY SUBMISSIONS	89
5.2.1 PRE-SUBMISSION ACTIVITIES	89
5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION	90
5.3 CLINICAL EVALUATION	90
5.4 REGULATORY SUBMISSION PREPARATION	90
5.5 SUBMISSION TO REGULATORY AUTHORITY	90
5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY	90
5.7 APPROVAL AND MARKET AUTHORIZATION	91
5.8 POST-MARKET SURVEILLANCE	91
5.9 RENEWAL AND COMPLIANCE	91
5.10 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD)	91
5.11 ADOPTION OF NORTH AMERICA STANDARDS (ISO AND IEC)	92
5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE	92
5.13 CLINICAL DATA HARMONIZATION	92
5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT	92
5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION	92
5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS)	92
5.17 TRAINING AND CAPACITY BUILDING INITIATIVES	93
5.18 NORTH AMERICA REGULATORY SCENARIO	93
5.19 MEDICAL DEVICE CLASSIFICATION	95
5.20 REGULATORY SUBMISSIONS	98
5.21 EUROPE REGULATORY SCENARIO	100
5.22 REGULATORY SUBMISSIONS	102
5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO	104
5.24 SOUTH AMERICA REGULATORY SCENARIO	111
5.25 INTERNATIONAL HARMONIZATION	115
6 MARKET OVERVIEW	119
6.1 DRIVERS	121
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE	121
6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS	121

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

6.1.3 INCREASE IN PATIENT AUTONOMY	122
6.1.4 RISE IN MOBILE HEALTH APPLICATIONS	122
6.2 RESTRAINTS	124
6.2.1 HIGH COST OF SELF INJECTORS	124
6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES	125
6.3 OPPORTUNITIES	126
6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS	126
6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION	127
6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE	128
6.4 CHALLENGES	129
6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES	129
6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS	129
7 NORTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE	131
7.1 OVERVIEW	132
7.2 SELF-INJECTION DEVICES	135
7.3 SELF-INJECTION FORMULATION	137
8 NORTH AMERICA SELF-INJECTIONS MARKET, BY DOSAGE FORM	138
8.1 OVERVIEW	139
8.2 SINGLE DOSE	142
8.3 MULTI-DOSE	142
9 NORTH AMERICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION	143
9.1 OVERVIEW	144
9.2 SUBCUTANEOUS	147
9.3 INTRA MUSCULAR	147
9.4 OTHERS	148
10 NORTH AMERICA SELF-INJECTIONS MARKET, BY APPLICATION	149
10.1 OVERVIEW	150
10.2 AUTOIMMUNE DISEASES	153
10.3 PAIN MANAGEMENT	154
10.4 EMERGENCY DRUGS	154
10.5 ONCOLOGY	155
10.6 HORMONAL DISORDERS	155
10.7 OTHERS	156
11 NORTH AMERICA SELF-INJECTIONS MARKET, BY AGE GROUP	157
11.1 OVERVIEW	158
11.2 ADULT	161
11.3 GERIATRIC	161
11.4 PEDIATRIC	162
12 NORTH AMERICA SELF-INJECTIONS MARKET, BY GENDER	163
12.1 OVERVIEW	164
12.2 MALE	167
12.3 FEMALE	167
13 NORTH AMERICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL	168
13.1 OVERVIEW	169
13.2 DIRECT TENDER	172
13.3 HOSPITAL PHARMACY	172
13.4 ONLINE PHARMACY	173

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

13.5 OTHERS	173
14 NORTH AMERICA SELF-INJECTIONS MARKET, BY REGION	174
14.1 NORTH AMERICA	177
15 NORTH AMERICA SELF-INJECTIONS MARKET: COMPANY LANDSCAPE	201
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	201
16 SWOT ANALYSIS	202
17 COMPANY PROFILES	203
17.1 NOVO NORDISK	203
17.1.1 COMPANY SNAPSHOT	203
17.1.2 REVENUE	204
17.1.3 COMPANY SHARE ANALYSIS	204
17.1.4 PRODUCT PORTFOLIO	205
17.1.5 RECENT DEVELOPMENT	206
17.2 JOHNSON & JOHNSON SERVICES, INC.	207
17.2.1 COMPANY SNAPSHOT	207
17.2.2 REVENUE ANALYSIS	207
17.2.3 COMPANY SHARE ANALYSIS	208
17.2.4 PRODUCT PORTFOLIO	208
17.2.5 RECENT DEVELOPMENT	208
17.3 BIOGEN	210
17.3.1 COMPANY SNAPSHOT	210
17.3.2 REVENUE ANALYSIS	210
17.3.3 PRODUCT PORTFOLIO	211
17.3.4 RECENT DEVELOPMENT	212
17.4 AMGEN INC.	213
17.4.1 COMPANY SNAPSHOT	213
17.4.2 REVENUE ANALYSIS	213
17.4.3 COMPANY SHARE ANALYSIS	214
17.4.4 PRODUCT PORTFOLIO	214
17.4.5 RECENT DEVELOPMENT	214
17.5 SANOFI	215
17.5.1 COMPANY SNAPSHOT	215
17.5.2 REVENUE ANALYSIS	215
17.5.3 COMPANY SHARE ANALYSIS	216
17.5.4 PRODUCT PORTFOLIO	216
17.5.5 RECENT DEVELOPMENT	217
17.6 ABBVIE INC.	218
17.6.1 COMPANY SNAPSHOT	218
17.6.2 REVENUE ANALYSIS	218
17.6.3 COMPANY SHARE ANALYSIS	219
17.6.4 PRODUCT PORTFOLIO	219
17.6.5 RECENT DEVELOPMENT	219
17.7 YPSOMED	220
17.7.1 COMPANY SNAPSHOT	220
17.7.2 REVENUE ANALYSIS	220
17.7.3 PRODUCT PORTFOLIO	221
17.7.4 RECENT DEVELOPMENT	221

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

17.8 BD	222
17.8.1 COMPANY SNAPSHOT	222
17.8.2 REVENUE ANALYSIS	222
17.8.3 PRODUCT PORTFOLIO	223
17.8.4 RECENT DEVELOPMENT	223
17.9 ASTRAZENECA	224
17.9.1 COMPANY SNAPSHOT	224
17.9.2 REVENUE ANALYSIS	224
17.9.3 PRODUCT PORTFOLIO	225
17.9.4 RECENT DEVELOPMENTS	225
17.10 APTARGROUP, INC.	226
17.10.1 COMPANY SNAPSHOT	226
17.10.2 REVENUE ANALYSIS	226
17.10.3 PRODUCT PORTFOLIO	227
17.10.4 RECENT DEVELOPMENTS	227
17.11 BAYER	228
17.11.1 COMPANY SNAPSHOT	228
17.11.2 REVENUE	228
17.11.3 PRODUCT PORTFOLIO	229
17.11.4 RECENT DEVELOPMENT	229
17.12 BAUSCH HEALTH COMPANIES INC.	230
17.12.1 COMPANY SNAPSHOT	230
17.12.2 REVENUE ANALYSIS	230
17.12.3 PRODUCT PORTFOLIO	231
17.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH	232
17.13.1 COMPANY SNAPSHOT	232
17.13.2 REVENUE ANALYSIS	233
17.13.3 PRODUCT PORTFOLIO	233
17.13.4 RECENT DEVELOPMENTS	234
17.14 CREDENCE MEDSYSTEMS, INC.	235
17.14.1 COMPANY SNAPSHOT	235
17.14.2 PRODUCT PORTFOLIO	235
17.14.3 RECENT DEVELOPMENT	237
17.15 DALI MEDICAL DEVICES	238
17.15.1 COMPANY SNAPSHOT	238
17.15.2 PRODUCT PORTFOLIO	238
17.15.3 RECENT DEVELOPMENT	241
17.16 ENABLE INJECTIONS	242
17.16.1 COMPANY SNAPSHOT	242
17.16.2 PRODUCT PORTFOLIO	242
17.16.3 RECENT DEVELOPMENTS	243
17.17 E3D ELCAM DRUG DELIVERY DEVICES	245
17.17.1 COMPANY SNAPSHOT	245
17.17.2 PRODUCT PORTFOLIO	245
17.17.3 RECENT DEVELOPMENT	247
17.18 F. HOFFMANN-LA ROCHE LTD	248
17.18.1 COMPANY SNAPSHOT	248

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

17.18.2 REVENUE ANALYSIS	248
17.18.3 PRODUCT PORTFOLIO	249
17.18.4 RECENT DEVELOPMENT	249
17.19 GSK PLC	250
17.19.1 COMPANY SNAPSHOT	250
17.19.2 REVENUE ANALYSIS	250
17.19.3 PRODUCT PORTFOLIO	251
17.19.4 RECENT DEVELOPMENTS	251
17.20 GERRESHEIMER AG	252
17.20.1 COMPANY SNAPSHOT	252
17.20.2 REVENUE ANALYSIS	252
17.20.3 PRODUCT PORTFOLIO	253
17.20.4 RECENT DEVELOPMENTS	254
17.21 HASELMEIER	255
17.21.1 COMPANY SNAPSHOT	255
17.21.2 PRODUCT PORTFOLIO	255
17.21.3 RECENT DEVELOPMENT	257
17.22 IPSEN BIOPHARMACEUTICALS, INC.	258
17.22.1 COMPANY SNAPSHOT	258
17.22.2 REVENUE ANALYSIS	259
17.22.3 PRODUCT PORTFOLIO	259
17.22.4 RECENT DEVELOPMENT	259
17.23 LILLY	260
17.23.1 COMPANY SNAPSHOT	260
17.23.2 REVENUE ANALYSIS	260
17.23.3 PRODUCT PORTFOLIO	261
17.23.4 RECENT DEVELOPMENT	261
17.24 MIDAS PHARMA GMBH	262
17.24.1 COMPANY SNAPSHOT	262
17.24.2 PRODUCT PORTFOLIO	262
17.24.3 RECENT DEVELOPMENT	262
17.25 MERCK & CO., INC.,	263
17.25.1 COMPANY SNAPSHOT	263
17.25.2 REVENUE ANALYSIS	263
17.25.3 PRODUCT PORTFOLIO	264
17.25.4 RECENT DEVELOPMENT	264
17.26 NOVARTIS AG	265
17.26.1 COMPANY SNAPSHOT	265
17.26.2 REVENUE ANALYSIS	266
17.26.3 PRODUCT PORTFOLIO	266
17.26.4 RECENT DEVELOPMENTS	266
17.27 NEMERA	268
17.27.1 COMPANY SNAPSHOT	268
17.27.2 PRODUCT PORTFOLIO	268
17.27.3 RECENT DEVELOPMENT	270
17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)	271
17.28.1 COMPANY SNAPSHOT	271

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

17.28.2	PRODUCT PORTFOLIO	271
17.28.3	RECENT DEVELOPMENT	272
17.29	OWEN MUMFORD	273
17.29.1	COMPANY SNAPSHOT	273
17.29.2	PRODUCT PORTFOLIO	273
17.29.3	RECENT DEVELOPMENT	273
17.30	PFIZER INC.	274
17.30.1	COMPANY SNAPSHOT	274
17.30.2	REVENUE ANALYSIS	274
17.30.3	PRODUCT PORTFOLIO	275
17.30.4	RECENT DEVELOPMENT	275
17.30.5	RECENT DEVELOPMENT	275
17.31	PHILIP MEDSIZE	276
17.31.1	COMPANY SNAPSHOT	276
17.31.2	PRODUCT PORTFOLIO	276
17.31.3	RECENT DEVELOPMENTS	277
17.32	PHARMAJET.	278
17.32.1	COMPANY SNAPSHOT	278
17.32.2	PRODUCT PORTFOLIO	278
17.32.3	RECENT DEVELOPMENT	278
17.33	PENJET	279
17.33.1	COMPANY SNAPSHOT	279
17.33.2	1.1.4 PRODUCT PORTFOLIO	279
17.33.3	RECENT DEVELOPMENT	279
17.34	RECIPHARM AB	280
17.34.1	COMPANY SNAPSHOT	280
17.34.2	PRODUCT PORTFOLIO	280
17.34.3	RECENT DEVELOPMENTS	281
17.35	SCHOTT PHARMA	282
17.35.1	COMPANY SNAPSHOT	282
17.35.2	PRODUCT PORTFOLIO	282
17.35.3	RECENT DEVELOPMENTS	283
17.36	SHL MEDICAL AG	284
17.36.1	COMPANY SNAPSHOT	284
17.36.2	PRODUCT PORTFOLIO	284
17.36.3	RECENT DEVELOPMENT	285
17.37	SOCIETE INDUSTRIELLE DE SONCEBOZ SA	286
17.37.1	COMPANY SNAPSHOT	286
17.37.2	PRODUCT PORTFOLIO	286
17.37.3	RECENT DEVELOPMENT	286
17.38	TERUMO CORPORATION	287
17.38.1	COMPANY SNAPSHOT	287
17.38.2	REVENUE ANALYSIS	287
17.38.3	PRODUCT PORTFOLIO	288
17.38.4	RECENT DEVELOPMENT	288
17.39	TAKEDA PHARMACEUTICAL COMPANY LIMITED	290
17.39.1	COMPANY SNAPSHOT	290

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



17.39.2 REVENUE ANALYSIS	291
17.39.3 PRODUCT PORTFOLIO	291
17.39.4 RECENT DEVELOPMENT	291
17.40 TEVA PHARMACEUTICALS	292
17.40.1 COMPANY SNAPSHOT	292
17.40.2 REVENUE	292
17.40.3 PRODUCT PORTFOLIO	293
17.40.4 RECENT DEVELOPMENT	293
17.41 UCB PHARMA	294
17.41.1 COMPANY SNAPSHOT	294
17.41.2 REVENUE	294
17.41.3 PRODUCT PORTFOLIO	295
17.41.4 RECENT DEVELOPMENT	295
17.42 WEST PHARMACEUTICAL SERVICES	296
17.42.1 COMPANY SNAPSHOT	296
17.42.2 REVENUE ANALYSIS	296
17.42.3 PRODUCT PORTFOLIO	297
17.42.4 RECENT DEVELOPMENTS	298
18 QUESTIONNAIRE	299
19 RELATED REPORTS	302

## North America Self-injections Market

Market Report | 2024-09-01 | 302 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com